Cellmover and Red Glead Discovery are awarded 15 Million NOK Eurostars Grant

Prestigious Eurostars program awarded funding to Cellmover and Red Glead Discovery! The grant will support the development of Cellmover’s nanobody-based checkpoint inhibitor therapy against lung cancer. In addition, a macrocyclic peptide approach will be pursued in parallel.

“RGD is perfectly positioned to support Cellmover, an innovative Norwegian biotech dedicated to immunotherapy as next-generation cancer treatment,” said Johan Evenäs, CEO of Red Glead. “Our capabilities within peptide and macrocycle drug design, computational and medicinal chemistry and ADMET will be instrumental in this project.”

The three-year project will focus on advancing CM101, Cellmover’s innovative therapy that leverages nanobody technology to overcome immune resistance in lung cancer.

For more information go to https://www.cellmover.com/news